Genetic Variation on Dolutegravir Pharmacokinetics and Relation to Safety and Efficacy Outcomes: a Systematic Review

Overview

Journal Pharmacogenomics

Specialties Genetics
Pharmacology

Date 2024 Dec 19

PMID 39697075

Authors

Lisanne A H Bevers

Rebecca L Jensen

Andrew Owen

Angela Colbers

Daniel F Carr

David M Burger

Affiliations

Soon will be listed here.

Abstract

Background: Dolutegravir (DTG) is an antiviral agent used for the treatment of HIV, however, there is uncertainty over the influence of genetic variation on DTG exposure, and whether it has clinical implications for the efficacy or toxicity in different populations. This systematic review aims to create an overview of the impact of pharmacogenomics (PGx) on DTG exposure, efficacy, and toxicity.

Methods: Publications up to 14 November 2023 were searched and articles were selected on the following criteria: original research articles providing data on people with HIV, data on PGx and either PK or PD or both PD and PGx.

Results: 711 records were identified, and after screening 10 articles were included. Commonly analyzed genes across the articles were , , , and . The most reported variant associated with PD variability was in , with carriers at higher risk of neuropsychiatric adverse events.

Conclusions: This review concludes that while PGx testing may help explain some variability in DTG pharmacokinetics when combined with therapeutic drug monitoring (TDM), current evidence is insufficient to support its routine clinical use. The role of PGx research for DTG remains relevant, especially in specific patient populations where interindividual PK variations are still unexplained.

References

Weiss J, Rose J, Storch C, Ketabi-Kiyanvash N, Sauer A, Haefeli W . Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother. 2007; 59(2):238-45. DOI: 10.1093/jac/dkl474. View

Cindi Z, Kawuma A, Maartens G, Bradford Y, Venter F, Sokhela S . Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus. J Infect Dis. 2022; 226(9):1616-1625. PMC: 9624457. DOI: 10.1093/infdis/jiac174. View

Elliot E, Wang X, Singh S, Simmons B, Vera J, Miller R . Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition. Clin Infect Dis. 2018; 68(1):87-95. DOI: 10.1093/cid/ciy426. View

Andreatta K, Sax P, Wohl D, DAntoni M, Liu H, Hindman J . Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy. J Antimicrob Chemother. 2024; 80(1):281-291. PMC: 11695908. DOI: 10.1093/jac/dkae407. View

Cusato J, Borghetti A, Teti E, Milesi M, Tettoni M, Bonora S . Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study. Metabolites. 2022; 12(12). PMC: 9781993. DOI: 10.3390/metabo12121202. View

Lepik K, Yip B, Ulloa A, Wang L, Toy J, Akagi L . Adverse drug reactions to integrase strand transfer inhibitors. AIDS. 2018; 32(7):903-912. DOI: 10.1097/QAD.0000000000001781. View

Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink H . Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2016; 18(1):56-63. DOI: 10.1111/hiv.12468. View

Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G . Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review. PLoS Med. 2016; 13(11):e1002160. PMC: 5089741. DOI: 10.1371/journal.pmed.1002160. View

Waalewijn H, Chan M, Bollen P, Mujuru H, Makumbi S, Kekitiinwa A . Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. Lancet HIV. 2022; 9(5):e341-e352. PMC: 9046096. DOI: 10.1016/S2352-3018(21)00292-7. View

10.

Barcelo C, Aouri M, Courlet P, Guidi M, Braun D, Gunthard H . Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. J Antimicrob Chemother. 2019; 74(9):2690-2697. DOI: 10.1093/jac/dkz217. View

11.

Yagura H, Watanabe D, Kushida H, Tomishima K, Togami H, Hirano A . Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis. 2017; 17(1):622. PMC: 5603066. DOI: 10.1186/s12879-017-2717-x. View

12.

Tsuchiya K, Hayashida T, Hamada A, Oka S, Gatanaga H . Brief Report: High Peak Level of Plasma Raltegravir Concentration in Patients With ABCB1 and ABCG2 Genetic Variants. J Acquir Immune Defic Syndr. 2016; 72(1):11-4. DOI: 10.1097/QAI.0000000000000893. View

13.

Griesel R, Hill A, Meintjes G, Maartens G . Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial. Wellcome Open Res. 2021; 6:1. PMC: 8063551. DOI: 10.12688/wellcomeopenres.16473.1. View

14.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

15.

Elliot E, Neary M, Else L, Khoo S, Moyle G, Carr D . Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics. J Antimicrob Chemother. 2020; 75(5):1259-1266. DOI: 10.1093/jac/dkz558. View

16.

Cottrell M, Hadzic T, Kashuba A . Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013; 52(11):981-94. PMC: 3805712. DOI: 10.1007/s40262-013-0093-2. View

17.

Penafiel J, de Lazzari E, Padilla M, Rojas J, Gonzalez-Cordon A, Blanco J . Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother. 2017; 72(6):1752-1759. DOI: 10.1093/jac/dkx053. View

18.

Borghetti A, Calcagno A, Lombardi F, Cusato J, Belmonti S, DAvolio A . SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. J Antimicrob Chemother. 2018; 74(4):1035-1043. DOI: 10.1093/jac/dky508. View

19.

Mulligan N, Best B, Wang J, Capparelli E, Stek A, Barr E . Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018; 32(6):729-737. PMC: 5854536. DOI: 10.1097/QAD.0000000000001755. View

20.

Chen S, St Jean P, Borland J, Song I, Yeo A, Piscitelli S . Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics. Pharmacogenomics. 2013; 15(1):9-16. DOI: 10.2217/pgs.13.190. View